|Bid||134.29 x 200|
|Ask||134.35 x 400|
|Day's Range||133.90 - 134.42|
|52 Week Range||110.79 - 136.45|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices into the red territory for the year and in the correction zone from the latest peak.Source: Investment Zen via Flickr (Modified)
When it comes to single-factor investing, growth and momentum ETFs have performed very well this year, and have attracted significant assets along the way. The lineup of growth and momentum ETFs, however, couldn’t be more different, making choosing a fund to ride the wave potentially tricky. From a performance perspective, both growth and momentum are benefiting from a slow-and-steady economy, according to Russ Koesterich, portfolio manager for BlackRock’s Global Allocation team.
In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.
On June 5, 2017, Edwards Lifesciences’ Sapien 3 valve was approved by the FDA for use in the aortic and mitral valve-in-valve procedure.
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis ...
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
Taking advantage of one of the greatest benefits of ETFs—transparency—can lead to some surprising discoveries. Case in point: the world of small-cap ETFs. We’ve discovered that while a number of ETFs call themselves “small-caps,” they really don't have that much small-cap exposure. And that matters, because a fund that isn’t exactly small-cap is going to deliver different risks and different returns than a pure small-cap strategy. Clarifying Terms
The Zacks Analyst Blog Highlights: iShares Core S&P Mid-Cap ETF, iShares Russell Mid-Cap ETF, Vanguard Mid-Cap Growth ETF, iShares S&P Mid-Cap 400 Growth ETF and Schwab U.S. Mid-Cap ETF
Mid-cap ETFs are arguably safer options and have the potential to move higher in turbulent times, especially if political issues or financial instability creeps into the picture.